Source-grounded facts extracted from Cingulate Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cingulate Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $12.0 million (effective 2023-04-24).
“On April 24, 2023, Cingulate Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $12.0 million of the Company’s common stock”
Jeff Conroy resigned as Director at Cingulate Inc..
“On January 5, 2023, Jeff Conroy provided Cingulate Inc. (the “Company”) with notice of his resignation from the Board of Directors.”
Cingulate Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at Aggregate gross proceeds of up to $2,650,000 (effective 2023-01-03).
“On January 3, 2023, Cingulate Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $2,650,000 (the “Shares”).”
Cingulate Inc. reported financial results for the quarter ended September 30, 2022.
“On November 14, 2022, Cingulate Inc. (the “Company”) issued a press release announcing its financial results for the third quarter of 2022 and providing a clinical and business update.”
Jeff Hargroves resigned as Director at Cingulate Inc..
“On September 23, 2022, Jeff Hargroves provided Cingulate Inc. (the “Company”) with notice of his resignation from the Board of Directors.”
Scott Applebaum was appointed as Class III Director at Cingulate Inc..
“On August 9, 2022, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, expanded the size of the Board to eight directors and appointed Scott Applebaum as a Class III director to serve until the Company’s 2024 annual meeting of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.